Dolby Laboratories

Valuation Analysis

About the Company

Dolby Laboratories en bref

Dolby Laboratories (DLB) is currently trading at 45,65 € with a market capitalization of 4,3 Md €. The trailing P/E ratio stands at 20.76x, with a forward P/E of 11.36x. The 52-week range spans from 44,27 € to 67,20 €; the current price is 32.1% below the yearly high. Year-over-year revenue growth stands at +7.1%. The net profit margin stands at 17.85%.

💰 Dividende

Dolby Laboratories pays an annual dividend of 1,23 € per share, representing a yield of 2.7%. The payout ratio stands at 54.76%.

📊 Avis des analystes

3 analystes évaluent Dolby Laboratories (DLB) au consensus : Acheter. L'objectif de cours moyen est de 68,36 €, soit un potentiel de +49.75% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 52,36 € à 78,54 €.

Dolby Laboratories : la thèse d'investissement en détail

Dolby Laboratories (DLB) operates in the Industrials — specifically Specialty Business Services — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 87.44%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 17.85%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions. Wall Street consensus sits at Buy with an average price target implying roughly 49.75% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Short interest sits at 11.08% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

The PEG ratio at 1.29 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

À surveiller

• The forward P/E of 11.36x is meaningfully below the trailing 20.76x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 49.75% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (11.08%).

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Dolby Laboratories?

Compare top-rated brokers — low fees, trusted providers, fully regulated.